Paper · 8620534

Role of the INK4a locus in tumor suppression and cell mortality.

Serrano M and 5 others. Cell, 1996. Cited by 1,389 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Role of the INK4a locus in tumor suppression and cell mortality. Papers, record 8620534. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8620534

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Role of the INK4a locus in tumor suppression and cell mortality.; PubMed
Journal: Cell; PubMed
Year: 1996; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/8620534/; PubMed
DOI: https://doi.org/10.1016/s0092-8674(00)81079-x; PubMed
The journal: https://conductscience.org/library/journal-index/0413066; PubMed
Citations, by iCite: 1,389; iCite
Relative citation ratio, by iCite: 25.1; iCite
Revised in PubMed: 2019-07-05; PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Serrano M	M
2	Lee H	H
3	Chin L	L
4	Cordon-Cardo C	C
5	Beach D	D
6	DePinho RA	R A

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Carrier Proteins	Major topic
Genes, Tumor Suppressor	Major topic
Alleles
Animals
Cell Death
Cell Division
Cell Transformation, Neoplastic
Cyclin-Dependent Kinase Inhibitor p16
Enzyme Inhibitors
Fibroblasts
Germ-Line Mutation
Humans
Mice
Mice, Inbred C57BL
Mice, Knockout
Phenotype
Proteins
Tumor Suppressor Protein p14ARF

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
CA09173	NCI NIH HHS	United States		PubMed	PubMed
EY09300	NEI NIH HHS	United States	R01EY009300	PubMed and NIH	NIH RePORTER
HD28317	NICHD NIH HHS	United States	R01HD028317	PubMed and NIH	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by604

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,389 citations.

PMID	Title	Journal	Year	In Papers	Source
42,941,778	Cellular Senescence in Ocular Surface Diseases: Molecular Mechanisms and Therapeutic Perspectives.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42941778	PubMed
42,585,180	Targeting telomeres in brain vasculature does not impede initiation and progression of glioblastoma.	PLoS One	2026	https://conductscience.org/library/papers/42585180	PubMed
42,128,941	Frequent expression of aberrant chimeric Cdkn2a transcripts in mouse models of muscular dystrophy.	Sci Rep	2026	https://conductscience.org/library/papers/42128941	PubMed
41,741,657	A disease model resource reveals core principles of tissue-specific cancer evolution.	Nature	2026	https://conductscience.org/library/papers/41741657	PubMed
41,601,660	Natural killer cell-based senotherapy: a promising strategy for healthy aging.	Front Immunol	2025	https://conductscience.org/library/papers/41601660	PubMed
41,405,992	STAT-independent functions of Janus kinases 1 and 2 are obligatory for the postnatal development of mammary epithelial ducts.	Cell Rep	2026	https://conductscience.org/library/papers/41405992	PubMed
41,029,757	Targeting immunosenesence promotes clearance of senescent cells.	Immun Ageing	2025	https://conductscience.org/library/papers/41029757	PubMed
40,872,623	Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.	Pharmaceuticals (Basel)	2025	https://conductscience.org/library/papers/40872623	PubMed
40,581,663	Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma.	Acta Neuropathol Commun	2025	https://conductscience.org/library/papers/40581663	PubMed
40,500,450	Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.	Nature	2025	https://conductscience.org/library/papers/40500450	PubMed

1 to 10 of 604

See all 604 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
CDKN2A	1,029	PubTator's text mining	https://conductscience.org/library/genes/1029

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8620534

GET https://conductscience.org/api/papers/v1/8620534/cited_by?page=2

API reference For AI assistants